Literature DB >> 16518403

Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.

Bert Gold1, Joanna E Merriam, Jana Zernant, Lisa S Hancox, Andrew J Taiber, Karen Gehrs, Kevin Cramer, Julia Neel, Julie Bergeron, Gaetano R Barile, R Theodore Smith, Gregory S Hageman, Michael Dean, Rando Allikmets.   

Abstract

Age-related macular degeneration (AMD) is the most common form of irreversible blindness in developed countries. Variants in the factor H gene (CFH, also known as HF1), which encodes a major inhibitor of the alternative complement pathway, are associated with the risk for developing AMD. Here we test the hypothesis that variation in genes encoding other regulatory proteins of the same pathway is associated with AMD. We screened factor B (BF) and complement component 2 (C2) genes, located in the major histocompatibility complex class III region, for genetic variation in two independent cohorts comprising approximately 900 individuals with AMD and approximately 400 matched controls. Haplotype analyses identify a statistically significant common risk haplotype (H1) and two protective haplotypes. The L9H variant of BF and the E318D variant of C2 (H10), as well as a variant in intron 10 of C2 and the R32Q variant of BF (H7), confer a significantly reduced risk of AMD (odds ratio = 0.45 and 0.36, respectively). Combined analysis of the C2 and BF haplotypes and CFH variants shows that variation in the two loci can predict the clinical outcome in 74% of the affected individuals and 56% of the controls. These data expand and refine our understanding of the genetic risk for AMD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518403      PMCID: PMC2921703          DOI: 10.1038/ng1750

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  29 in total

Review 1.  An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration.

Authors:  G S Hageman; P J Luthert; N H Victor Chong; L V Johnson; D H Anderson; R F Mullins
Journal:  Prog Retin Eye Res       Date:  2001-11       Impact factor: 21.198

Review 2.  Epidemiology of age-related maculopathy: a review.

Authors:  Redmer van Leeuwen; Caroline C W Klaver; Johannes R Vingerling; Albert Hofman; Paulus T V M de Jong
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

3.  Drusen proteome analysis: an approach to the etiology of age-related macular degeneration.

Authors:  John W Crabb; Masaru Miyagi; Xiaorong Gu; Karen Shadrach; Karen A West; Hirokazu Sakaguchi; Motohiro Kamei; Azeem Hasan; Lin Yan; Mary E Rayborn; Robert G Salomon; Joe G Hollyfield
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

Review 4.  The alternative pathway of complement in disease: opportunities for therapeutic targeting.

Authors:  V Michael Holers; Joshua M Thurman
Journal:  Mol Immunol       Date:  2004-06       Impact factor: 4.407

5.  A fine-scale map of recombination rates and hotspots across the human genome.

Authors:  Simon Myers; Leonardo Bottolo; Colin Freeman; Gil McVean; Peter Donnelly
Journal:  Science       Date:  2005-10-14       Impact factor: 47.728

6.  Complement activation and inflammatory processes in Drusen formation and age related macular degeneration.

Authors:  L V Johnson; W P Leitner; M K Staples; D H Anderson
Journal:  Exp Eye Res       Date:  2001-12       Impact factor: 3.467

7.  Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease.

Authors:  R F Mullins; S R Russell; D H Anderson; G S Hageman
Journal:  FASEB J       Date:  2000-05       Impact factor: 5.191

Review 8.  A role for local inflammation in the formation of drusen in the aging eye.

Authors:  Don H Anderson; Robert F Mullins; Gregory S Hageman; Lincoln V Johnson
Journal:  Am J Ophthalmol       Date:  2002-09       Impact factor: 5.258

Review 9.  The epidemiology of age-related macular degeneration.

Authors:  Ronald Klein; Tunde Peto; Alan Bird; Mylan R Vannewkirk
Journal:  Am J Ophthalmol       Date:  2004-03       Impact factor: 5.258

10.  Immunoglobulin deficiencies and susceptibility to infection among homozygotes and heterozygotes for C2 deficiency.

Authors:  Chester A Alper; Jianhua Xu; Katherine Cosmopoulos; Brian Dolinski; Rosanne Stein; Gabriel Uko; Charles E Larsen; Devendra P Dubey; Peter Densen; Lennart Truedsson; Gunnar Sturfelt; Anders G Sjöholm
Journal:  J Clin Immunol       Date:  2003-07       Impact factor: 8.317

View more
  468 in total

Review 1.  Dynamic control of the complement system by modulated expression of regulatory proteins.

Authors:  Joshua M Thurman; Brandon Renner
Journal:  Lab Invest       Date:  2010-10-04       Impact factor: 5.662

2.  Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement.

Authors:  Mausumi Bandyopadhyay; Bärbel Rohrer
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-18       Impact factor: 4.799

3.  Automated discovery and quantification of image-based complex phenotypes: a twin study of drusen phenotypes in age-related macular degeneration.

Authors:  Gwenole Quellec; Stephen R Russell; Johanna M Seddon; Robyn Reynolds; Todd Scheetz; Vinit B Mahajan; Edwin M Stone; Michael D Abràmoff
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-25       Impact factor: 4.799

4.  Prospective assessment of genetic effects on progression to different stages of age-related macular degeneration using multistate Markov models.

Authors:  Yi Yu; Robyn Reynolds; Bernard Rosner; Mark J Daly; Johanna M Seddon
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-21       Impact factor: 4.799

Review 5.  Complement dysregulation in AMD: RPE-Bruch's membrane-choroid.

Authors:  Janet R Sparrow; Keiko Ueda; Jilin Zhou
Journal:  Mol Aspects Med       Date:  2012-04-05

Review 6.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

7.  Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.

Authors:  Zohar Yehoshua; Carlos Alexandre de Amorim Garcia Filho; Renata Portella Nunes; Giovanni Gregori; Fernando M Penha; Andrew A Moshfeghi; Kang Zhang; Srinivas Sadda; William Feuer; Philip J Rosenfeld
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

Review 8.  Age-related macular degeneration: genetics and biology coming together.

Authors:  Lars G Fritsche; Robert N Fariss; Dwight Stambolian; Gonçalo R Abecasis; Christine A Curcio; Anand Swaroop
Journal:  Annu Rev Genomics Hum Genet       Date:  2014-04-16       Impact factor: 8.929

9.  Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population.

Authors:  R Martínez-Barricarte; E Goicoechea de Jorge; T Montes; A G Layana; S Rodríguez de Córdoba
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

10.  Search for age-related macular degeneration risk variants in Alzheimer disease genes and pathways.

Authors:  Mark W Logue; Matthew Schu; Badri N Vardarajan; John Farrell; Kathryn L Lunetta; Gyungah Jun; Clinton T Baldwin; Margaret M Deangelis; Lindsay A Farrer
Journal:  Neurobiol Aging       Date:  2013-12-19       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.